GnRH

ApprovedSmall molecule

MMassachusetts General Hospital

GnRH is one of 178 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

177

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

HyperprolactinemiaActive, not recruiting

Hypogonadotropic HypogonadismActive, not recruiting

Delayed PubertyActive, not recruiting

Metabolic DiseaseActive, not recruiting

Prostate CancerActive, not recruiting

Prostatic NeoplasmsActive, not recruiting

InfertilityRecruiting

Metabolic SyndromePreclinical

Active, not recruiting

HyperprolactinemiaPhase 2

Active, not recruiting

Hypogonadotropic HypogonadismPhase 2

Active, not recruiting

Delayed PubertyPhase 1

Active, not recruiting

Metabolic DiseasePreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

InfertilityApproved

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

GnRH

MMassachusetts General Hospital

Approved

2 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Duragesic

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Metabolic Syndrome

NCT02653092

Q4 2028

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT02531516

Clinical

Trials by Indication[1]

Infertility2 trials

Pulsatile GnRH in Anovulatory Infertility

Unknown status·MMassachusetts General Hospital·Phase 2·NCT00383656·270 enrolled

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Recruiting·UUniversity Reproductive Associates·Approved·NCT02357654·350 enrolled

Prostate Cancer2 trials

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00587431·102 enrolled

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00586898·36 enrolled

ISS1 trial

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Completed·MMassachusetts General Hospital·Phase 1·NCT01438073·96 enrolled

Peptides1 trial

Neuropeptides in Human Reproduction

Completed·MMassachusetts General Hospital·Phase 1·NCT01952782·61 enrolled

Metabolic Syndrome1 trial

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active, not recruiting·UUniversity of Colorado, Denver·N/A·NCT02653092·84 enrolled

10 more indications

Delayed puberty1 trial

Kisspeptin in the Evaluation of Delayed Puberty

Completed·MMassachusetts General Hospital·Phase 1·NCT01438034·24 enrolled

Metabolic Disease1 trial

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

Unknown status·RRoyal College of Surgeons, Ireland··NCT05773183·60 enrolled

Hypogonadotropic Hypogonadism1 trial

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Completed·—·Phase 2·NCT04648969·18 enrolled

Obese Women1 trial

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

Completed·UUniversity of Colorado, Denver·N/A·NCT01894581·39 enrolled

Hyperprolactinemia1 trial

Administration of Kisspeptin in Patients With Hyperprolactinemia

Completed·MMassachusetts General Hospital·Phase 2·NCT02956447·36 enrolled

Acute Lymphoblastic Leukemia1 trial

Recall by Genotype: Neuropeptide Stimulation

Terminated·—·Phase 1·NCT05901467·16 enrolled

Adult1 trial

Kisspeptin Administration in the Adult

Completed·MMassachusetts General Hospital·Phase 1·NCT00914823·256 enrolled

Randomized1 trial

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Active, not recruiting·—·Phase 2·NCT03141671·345 enrolled

Estrogen1 trial

The Effects of Aging and Estrogen on the Pituitary

Unknown status·MMassachusetts General Hospital·Phase 2/3·NCT00386022·19 enrolled

Prostatic Neoplasms1 trial

ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT02531516·1,503 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for GnRH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMassachusetts General Hospital

GnRH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Infertility2 trials

Prostate Cancer2 trials

ISS1 trial

Peptides1 trial

Metabolic Syndrome1 trial

Delayed puberty1 trial

Metabolic Disease1 trial

Hypogonadotropic Hypogonadism1 trial

Obese Women1 trial

Hyperprolactinemia1 trial

Acute Lymphoblastic Leukemia1 trial

Adult1 trial

Randomized1 trial

Estrogen1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News